BLTE · ISSUER CIK 1889109
BELITE BIO, INC
Between Aug 1, 2026 and Oct 29, 2026, 3 BELITE BIO, INC insiders reported $0.00 of open-market purchases and $32.1M of sales on SEC Form 4.
↗3 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 5 of 5 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$32.1MInsider selling
−$32.1MNet open-market
Oct 5, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 5, 202619:27 | Oct 1, 2026 | BLTE | Chief Medical Officer | S · Sell10b5-1 | $165.32 | −500 | 14,500 | -3% | −$83K | ||
| Sep 9, 202619:39 | Sep 8, 2026from Sep 4, 2026 | BLTE | Chief Executive Officer, Director | S · Sell10b5-1 | $190.00 | −100,435 | 70,134 | -59% | −$19.1M | ||
| Sep 9, 202619:38 | Sep 8, 2026from Sep 4, 2026 | BLTE | Chief Financial Officer, Director | S · Sell10b5-1 | $189.98 | −67,395 | 26,038 | -72% | −$12.8M | ||
| Aug 14, 202606:10 | Aug 12, 2026 | BLTE | Chief Financial Officer, Director | S · Sell10b5-1 | $180.35 | −367 | 93,433 | -0% | −$66K | ||
| Aug 14, 202606:10 | Aug 12, 2026 | BLTE | Chief Executive Officer, Director | S · Sell10b5-1 | $180.35 | −365 | 170,569 | -0% | −$66K |